Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420 Article

Lieberman, Frank S, Wang, Meihua, Robins, H Ian et al. (2019). Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420 . INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 103(4), 878-886. 10.1016/j.ijrobp.2018.11.008

Open Access Industry Collaboration

cited authors

  • Lieberman, Frank S; Wang, Meihua; Robins, H Ian; Tsien, Christina; Curran, Walter J; Werner-Wasik, Maria; Smith, Ryan P; Schultz, Christopher; Hartford, Alan C; Zhang, Peixin; Mehta, Minesh P

sustainable development goals

authors

publication date

  • March 15, 2019

webpage

published in

keywords

  • ADJUVANT
  • BEVACIZUMAB
  • CONCOMITANT
  • CPT-11
  • Life Sciences & Biomedicine
  • NEWLY-DIAGNOSED GLIOBLASTOMA
  • Oncology
  • PSEUDOPROGRESSION
  • Radiology, Nuclear Medicine & Medical Imaging
  • Science & Technology

Digital Object Identifier (DOI)

publisher

  • ELSEVIER SCIENCE INC

start page

  • 878

end page

  • 886

volume

  • 103

issue

  • 4